Antibody therapeutics companies develop engineered antibodies that target specific molecules involved in disease. These medicines are used across oncology, autoimmune disease, inflammatory conditions, infectious disease and other areas of clinical development.
This category includes companies working on:
Browse 75 UK antibody therapeutics companies below.
Antibody therapeutics for inflammatory and autoimmune disease
MabGalaxy develops antibody therapeutics for inflammatory and autoimmune diseases, with scientific operations linked to Cambridge's Babraham Research Campus. Its discovery approach combines immune-system biology with artificial intelligence to support antibody design and selection. The company aims to shorten the…
Global biopharma with UK R&D hub in Hertfordshire
Roche Products is the UK pharmaceutical arm of F. Hoffmann-La Roche, headquartered at Welwyn Garden City in Hertfordshire. The site employs over 1,900 people and serves as a primary hub for early-stage drug discovery, clinical development, computational sciences, and commercial operations. The UK operation contributes…
IgE and IgA antibody therapeutics for cancer treatment
Epsilogen is a clinical-stage biotech pioneering the development of non-IgG immunoglobulin antibody therapeutics for cancer. The company's platform spans IgE, IgA, and IgG isotypes, enabling selection of the most appropriate antibody format for a given tumour type. Its lead candidate MOv18 IgE, the first IgE antibody…
Bispecific antibody platform for cancer immunotherapies
F-star Therapeutics is a clinical-stage biotechnology company developing tetravalent bispecific antibodies for cancer and other serious diseases. Its proprietary platform creates antibodies with four binding sites that simultaneously target two different antigens, enabling focused immune activation in the tumour…
Global diabetes and cardiometabolic medicines leader
Novo Nordisk Limited is the UK commercial and medical affiliate of Novo Nordisk A/S, the Danish pharmaceutical company focused on diabetes, obesity, and cardiometabolic disease. The UK operation covers commercialisation, medical affairs, and clinical trial activities. Separately, Novo Nordisk Research Centre Oxford…
Global biopharma focused on neurology and rare disease therapeutics
Biogen is a global biopharma company and one of the world's first biotechnology firms. The UK and Ireland headquarters in Maidenhead employs approximately 250 people across clinical operations, regulatory affairs, drug safety, and medical affairs. The company develops and commercialises therapies for neurological,…
Antibody therapeutics targeting glycosphingolipid inflammation
Protalea Bio is a biotech company developing first-in-class therapeutic antibodies to prevent progression from precancerous states to active blood cancers including multiple myeloma and B-cell lymphoma. The company's approach targets glycosphingolipid-related inflammation before disease onset, building on over fifteen…
Antibody therapies targeting severe autoimmune diseases
argenx UK Ltd is the UK commercial subsidiary of argenx SE, a global immunology company developing antibody-based therapies for severe autoimmune diseases. The company markets VYVGART (efgartigimod), the first approved FcRn blocker in the UK, indicated for generalised myasthenia gravis and chronic inflammatory…
Clinical-stage oncology company advancing in-licensed cancer drug assets
Ellipses Pharma is a clinical-stage oncology drug development company that in-licenses cancer drug assets from academia and industry, advances them through clinical trials using a continuous funding model, and out-licenses at value-inflection points. Its pipeline spans small molecule kinase inhibitors, selective…
Global biopharmaceutical company developing therapies for serious diseases
AbbVie is a global research-based biopharmaceutical company focused on the discovery, development and commercialisation of medicines across immunology, oncology, neuroscience and aesthetics. Its portfolio includes treatments for autoimmune diseases, haematological cancers, neurological conditions and women's health.…
Antibody discovery biotech targeting GPCRs in inflammatory disease
DJS Antibodies is a biotechnology company developing monoclonal antibody therapeutics against G protein-coupled receptors and other previously intractable disease targets. Its proprietary antibody discovery platform enables the generation of first-in-class antibodies against transmembrane proteins that have…
Clinical-stage bispecific antibody therapies for cancer and blood disease
NovalGen is a clinical-stage biotechnology company developing multi-specific biologics for oncology, haematological malignancies, and autoimmune diseases. Its proprietary platform embeds a feedback mechanism into therapeutic biologics that deactivates the drug in response to excessive immune activation, aiming to…
UK affiliate of global innovative medicines company Novartis AG
Novartis Pharmaceuticals UK Limited is the UK commercial and medical affiliate of Novartis AG, the Swiss-headquartered global pharmaceutical company. Headquartered at White City Place in London, the UK operation employs approximately 1,300 people and focuses on commercialisation, medical affairs, regulatory…
Clinical-stage antibody-drug conjugate specialist targeting solid tumours
Pheon Therapeutics is a clinical-stage biotechnology company developing a pipeline of antibody-drug conjugates for the treatment of solid tumours. The company combines monoclonal antibodies with proprietary cytotoxic payloads and linker technologies, taking a target-specific approach to optimising each construct for…
Intranasal anti-CD3 immunotherapy for neuroinflammatory diseases
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing immunomodulatory therapies for neurological and inflammatory diseases. Its lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody designed to modulate T-cell activity through nasal administration. The 48-patient…
Macrophage-targeted therapeutics for oncology, neurological and fibrotic diseases
Macomics is a University of Edinburgh spin-out developing macrophage-targeted medicines across oncology, neurodegenerative, inflammatory and fibrotic diseases. Its ENIGMAC drug discovery platform combines human macrophage and microglia models derived from induced pluripotent stem cells, gene editing and…
ADC oncology company developing novel spliceosome-modulating payloads
Akari Therapeutics is a clinical-stage biopharma company developing next-generation bi-functional antibody-drug conjugates for cancer treatment. Its proprietary ADC platform centres on PH1, a novel spliceosome-modulating small molecule payload designed to disrupt RNA splicing in tumour cells and activate anti-tumour…
CAR-T and bispecific antibody therapies for blood cancers
Hemogenyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for haematological malignancies and autoimmune diseases. Its lead asset, HG-CT-1, is a third-generation anti-FLT3 CAR-T cell therapy for relapsed and refractory acute myeloid leukaemia, currently in a Phase 1…
DNA damage response platform targeting hard-to-treat solid tumours
Artios Pharma is a clinical-stage biopharmaceutical company developing small molecule therapeutics that target DNA damage response pathways in cancer cells. The company's pipeline includes alnodesertib, an ATR inhibitor advancing toward late-stage development in ATM-deficient solid tumours, and ART6043, a DNA…
Global biopharma with UK R&D centre on the Wirral Peninsula
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company with a long-established UK R&D site at Moreton on the Wirral Peninsula and its UK and Ireland commercial headquarters in Uxbridge. The Moreton facility, expanded in 2025, conducts chemistry, manufacturing and control activities supporting pharmaceutical…